POROUS PLASTIC MATRIX TABLETS OF LEVETIRACETAM FOR ZERO-ORDER CONTROLLED RELEASE: DEVELOPMENT AND FORMULATION OPTIMIZATION
Objective:The prior objective of the current research work was to develop a once daily levetiracetam extended-release tablets having zero-order release kinetics with plastic matrix as the release retarding element. For a high water-soluble drug, the formulation of a dosage form so as to have an extended drug release has always been a difficult task. Methods:In the current work, levetiracetam which is a highly soluble drug was taken as the model drug for which extended-release matrix tablets were developed using varied plastic polymers like Polyvinyl acetate (PVAc), Polyvinyl chloride (PVC), Eudragit RSPO and Eudragit RLPO. PVP was considered as a pore forming agent and PEG 6000 was taken as water regulating agent. The porous plastic matrix tablets were prepared by embedding the drug in solvent-activated polymer dispersion followed bydrying, sieving, mixing with other excipients and finally compressed. Including physical characterization studies and drug release studies, the tablets were subjected to SEM studies before and after the dissolution studies to analyze the effect of the pore former. Results: The tablets were strong enough with good tensile strength and less friability. Drug release study results of all the formulations showed that the time of drug release was controlled for a period of 12 – 24hr. PVAc had shown better control release among all the plastic polymers taken.PVP and PEG 600 showed significant influence on the drug release. Conclusion:Thelevetiracetam porous plastic matrix tablets were developed with zero-order release of drug that was effectively controlled for a period of 24hr.
2. Patel H, Panchal DR, Patel U, Brahmbhatt T, Suthar M. Matrix type drug delivery system: A review. J Pharm Sci Bio-sci Res. 2011;1(3):143- 51.
3. Reza MS, Quadi MA, Haider SS. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery. J Pharm Pharmaceut Sci. 2003;6(2):282-91.
4. Apu AS, Pathan AH, Shrestha D, Kibria G,Jalil R. Investigation of in vitro release kinetics of carbamazepine from Eudragit RSPO and RLPO matrix tablets. Trop J Pharm Res. 2009;8(2):145
5. Tabandeh H,MortazaviSA, Guilani TB. Preparation of sustained-release matrix tablets of aspirin with ethylcellulose, Eudragit RS100 and Eudragit S100 and studying the release profiles and their sensitivity to tablet hardness. Iran. J. Pharm. Sci. 2003;2(4):201-6.
6. Pundir S, Badola A, Sharma D. Sustained release matrix technology and recent advance in matrix drug delivery system: A review, Int J Drug ResTech. 2013;3(1):12-20.
7. Singh S, Bhavesh S, SanjaykumarN, Sunil B. Formulation and evaluation of levetiracetam extended release tablets. IntJPharm SciNanotech. 2003;6(1):1958-65.
8. Alhalmi A, Altowairi M, Saeed O, Alzubaidi N, Almoiliqy M, Abdulmalik W. Sustained release matrix system: An overview. World J Pharm Pharm Sci. 2018;7(6):1470-86.
9. Karvekar M, Khan AB. A brief review on sustained release matrix type drug delivery system. J Pharm Res. 2017;16(3):282-9.
10. Mohammed SS. Preparation, characterization and preformulation studies of diltiazem sustain release tablet. Asian J Res Pharm SciBiotechnol. 2014;2(1):16-22.
11. Chavan PM,Ughade S. Preparation, characterization and evaluation of tablet for colonic delivery. IntJPharm SciRes. 2018;9(5):2027-33.
12. Eichie, FE,Kudehinbu, AO. Effect of particle size of granules on some mechanical properties of paracetamol tablets. Afr JBiotechnol. 2009;8(21):5913-6.
13. Zaid AN, Al-Ramahi RJ, Ghoush AA, Qaddumi A, Zaroor YA. Weight and content uniformity of lorazepam half tablets: A study of correlation of low drug content product. Saudi Pharm J. 2013;21:71-5.
14. VijayaDurga. K, Ashok Kumar. P, Kulkarni SV. Influence of natural, synthetic polymers and fillers on sustained release matrix tablets of pregabalin.Int J Drug DevRes. 2013;5 (4):252-67.
15. S. Sivaneswari, E. Karthikeyan, P.J. Chandana. Novel expandable gastro retentive system by unfolding mechanism of levetiracetam using simple lattice design – Formulation optimization and in vitro evaluation. Bull Fac Pharm Cairo Univ. 2017;55(1):63-72.
16. Row RC, Shesky PJ, Owen SC, editors. Handbook of pharmaceutical excipients. London: Pharmaceutical Press; 2006.
17. Keller PE, Kouzes R. Water vapor permeation in plastics. Pacific northwest national laboratory: Washington; 2007.
18. Maskova E, Naiserova M, Kubova K, MasekJ, Pavlokovs S, UrbanovaM et. al.Highly soluble drugs directly granulated by water dispersions of insoluble Eudragit polymers as a part of Hypromellose K100M matrix systems. BioMed Res Int. 2019;Article ID 8043415.
19. D’souza AA. Shegokar R. Polyethylene glycol (PEG): A versatile polymer forpharmaceutical applications. Expert Opin Drug Deliv. 2016;13(9):1257-1275.
20. Robinson JR, Lee VHL., editors. Controlled drug delivery – Fundamentals and Applications. New York: Informa Healthcare; 2011.
21. Yang M, Xie S, Li Q, Wang Y, Chang X, Shan L et. al.Effects of polyvinylpyrrolidone both as a binder and pore-former on therelease of sparingly water-soluble topiramate from ethylcellulose coated pellets. Int J Pharm. 2014;465:187-96.
22. Hwang JR, Sefton MV. The effects of polymer concentration and a pore-forming agent(PVP) on HEMA-MMA microcapsule structure and permeability. J Membr Sci. 1995;108:257-68.
This work is licensed under a Creative Commons Attribution 4.0 International License.